Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 778.90K | 700.90K | 884.20K | 701.20K | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.38M | 1.10M | 884.20K | 701.20K | 1.12M |
| Operating Income | -1.38M | -1.10M | -884.20K | -701.20K | -1.12M |
| Income Before Tax | -1.41M | -1.12M | -8.17M | -1.82M | 113.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.41M | -1.12M | -8.17M | -1.82M | 113.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.41M | -1.12M | -8.17M | -1.82M | 113.30K |
| EBIT | -1.38M | -1.10M | -884.20K | -701.20K | -1.12M |
| EBITDA | -1.38M | -1.10M | -883.70K | -700.60K | -1.12M |
| EPS Basic | -1.45 | -1.56 | -15.07 | -3.38 | 0.24 |
| Normalized Basic EPS | -0.92 | -0.98 | -1.16 | -2.76 | -1.71 |
| EPS Diluted | -1.45 | -1.56 | -15.07 | -3.38 | 0.24 |
| Normalized Diluted EPS | -0.92 | -0.98 | -1.16 | -2.76 | -1.71 |
| Average Basic Shares Outstanding | 968.00K | 720.00K | 542.00K | 540.20K | 466.00K |
| Average Diluted Shares Outstanding | 968.00K | 720.00K | 542.00K | 540.20K | 466.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |